Article
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Leukemia & lymphoma - 1 Apr 2013
Macdonald David A, Assouline Sarit E, Brandwein Joseph, Kamel-Reid Suzanne, Eisenhauer Elizabeth A, Couban Stephen, Caplan Stephen, Foo Alison, Walsh Wendy, Leber Brian
Abstract excerpt
Sorafenib is active in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The National Cancer Institute of Canada (NCIC) Clinical Trials Group initiated a phase I/II study of the combination of sorafenib with cytarabine in older patients with AML or high-risk MDS who were unsuitable for intensive chemotherapy. FLT3 mutational status was determined in all patients. Twenty-one patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.